Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orthofix’ $150 Mil. Breg Purchase Will Produce PoC “Gatekeeper” – CEO

This article was originally published in The Gray Sheet

Executive Summary

Orthofix will gain access to Breg Inc.'s sales and distribution relationships with general orthopedic offices as part of a $150 mil. acquisition to expand into spinal, reconstruction and trauma orthopedic franchises

You may also be interested in...



Orthofix Cervical-Stim PMA Filing Almost Complete; Firm Settles With TriCare

Regulations governing TriCare coverage policies do not prohibit reimbursement of FDA-approved products for off-label uses, Orthofix maintains, despite paying $1.7 mil. in a billing investigation settlement with the Department of Justice

Orthofix Readies For Bone Protein Product; Cites Hurdles For Acceptance

Orthofix is exploring the possibility of conducting clinical trials with its electrical stimulation products and Medtronic's InFuse BMP-2 to demonstrate a benefit for bone morphogenetic protein when used in conjunction with e-stim

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel